Cargando…

Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)

BACKGROUND: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This study investigated the co-expression of ZEB-1 and E-cadherin in HCC by...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashiguchi, Motoyuki, Ueno, Shinichi, Sakoda, Masahiko, Iino, Satoshi, Hiwatashi, Kiyokazu, Minami, Koji, Ando, Kei, Mataki, Yuko, Maemura, Kosei, Shinchi, Hiroyuki, Ishigami, Sumiya, Natsugoe, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235016/
https://www.ncbi.nlm.nih.gov/pubmed/24304617
http://dx.doi.org/10.1186/1471-2407-13-572
_version_ 1782344950844751872
author Hashiguchi, Motoyuki
Ueno, Shinichi
Sakoda, Masahiko
Iino, Satoshi
Hiwatashi, Kiyokazu
Minami, Koji
Ando, Kei
Mataki, Yuko
Maemura, Kosei
Shinchi, Hiroyuki
Ishigami, Sumiya
Natsugoe, Shoji
author_facet Hashiguchi, Motoyuki
Ueno, Shinichi
Sakoda, Masahiko
Iino, Satoshi
Hiwatashi, Kiyokazu
Minami, Koji
Ando, Kei
Mataki, Yuko
Maemura, Kosei
Shinchi, Hiroyuki
Ishigami, Sumiya
Natsugoe, Shoji
author_sort Hashiguchi, Motoyuki
collection PubMed
description BACKGROUND: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This study investigated the co-expression of ZEB-1 and E-cadherin in HCC by immunohistochemistry and evaluated its association with clinical factors, including patient prognosis. METHODS: A total of 108 patients with primary HCC treated by curative hepatectomy were enrolled. ZEB-1 expression was immunohistochemically categorized as positive if at least 1% cancer cells exhibited nuclear staining. E-cadherin expression was divided into preserved and reduced expression groups and correlations between ZEB-1 and E-cadherin expression and clinical factors were then evaluated. RESULTS: With respect to ZEB-1 expression, 23 patients were classified into the positive group and 85 into the negative group. Reduced E-cadherin expression was seen in 44 patients and preserved expression in the remaining 64 patients. ZEB-1 positivity was significantly associated with reduced expression of E-cadherin (p = 0.027). Moreover, significant associations were found between ZEB-1 expression and venous invasion and TNM stage. ZEB-1 positivity was associated with poorer prognosis (p = 0.025). Reduced E-cadherin expression was significantly associated with intrahepatic metastasis and poorer prognosis (p = 0.047). In particular, patients with both ZEB-1 positivity and reduced E-cadherin expression had a poorer prognosis (p = 0.005). Regardless of E-cadherin status, ZEB-1 was not a significant prognostic factor by multivariate analysis. There was no statistical difference in overall survival when E-cadherin expression was reduced in the ZEB-1 positive group (p = 0.24). CONCLUSIONS: Positive ZEB-1 expression and loss of E-cadherin expression are correlated with poor prognosis in HCC patients and malignancy of ZEB-1 positive tumors involves EMT.
format Online
Article
Text
id pubmed-4235016
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42350162014-11-19 Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) Hashiguchi, Motoyuki Ueno, Shinichi Sakoda, Masahiko Iino, Satoshi Hiwatashi, Kiyokazu Minami, Koji Ando, Kei Mataki, Yuko Maemura, Kosei Shinchi, Hiroyuki Ishigami, Sumiya Natsugoe, Shoji BMC Cancer Research Article BACKGROUND: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This study investigated the co-expression of ZEB-1 and E-cadherin in HCC by immunohistochemistry and evaluated its association with clinical factors, including patient prognosis. METHODS: A total of 108 patients with primary HCC treated by curative hepatectomy were enrolled. ZEB-1 expression was immunohistochemically categorized as positive if at least 1% cancer cells exhibited nuclear staining. E-cadherin expression was divided into preserved and reduced expression groups and correlations between ZEB-1 and E-cadherin expression and clinical factors were then evaluated. RESULTS: With respect to ZEB-1 expression, 23 patients were classified into the positive group and 85 into the negative group. Reduced E-cadherin expression was seen in 44 patients and preserved expression in the remaining 64 patients. ZEB-1 positivity was significantly associated with reduced expression of E-cadherin (p = 0.027). Moreover, significant associations were found between ZEB-1 expression and venous invasion and TNM stage. ZEB-1 positivity was associated with poorer prognosis (p = 0.025). Reduced E-cadherin expression was significantly associated with intrahepatic metastasis and poorer prognosis (p = 0.047). In particular, patients with both ZEB-1 positivity and reduced E-cadherin expression had a poorer prognosis (p = 0.005). Regardless of E-cadherin status, ZEB-1 was not a significant prognostic factor by multivariate analysis. There was no statistical difference in overall survival when E-cadherin expression was reduced in the ZEB-1 positive group (p = 0.24). CONCLUSIONS: Positive ZEB-1 expression and loss of E-cadherin expression are correlated with poor prognosis in HCC patients and malignancy of ZEB-1 positive tumors involves EMT. BioMed Central 2013-12-05 /pmc/articles/PMC4235016/ /pubmed/24304617 http://dx.doi.org/10.1186/1471-2407-13-572 Text en Copyright © 2013 Hashiguchi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hashiguchi, Motoyuki
Ueno, Shinichi
Sakoda, Masahiko
Iino, Satoshi
Hiwatashi, Kiyokazu
Minami, Koji
Ando, Kei
Mataki, Yuko
Maemura, Kosei
Shinchi, Hiroyuki
Ishigami, Sumiya
Natsugoe, Shoji
Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
title Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
title_full Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
title_fullStr Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
title_full_unstemmed Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
title_short Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
title_sort clinical implication of zeb-1 and e-cadherin expression in hepatocellular carcinoma (hcc)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235016/
https://www.ncbi.nlm.nih.gov/pubmed/24304617
http://dx.doi.org/10.1186/1471-2407-13-572
work_keys_str_mv AT hashiguchimotoyuki clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT uenoshinichi clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT sakodamasahiko clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT iinosatoshi clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT hiwatashikiyokazu clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT minamikoji clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT andokei clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT matakiyuko clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT maemurakosei clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT shinchihiroyuki clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT ishigamisumiya clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc
AT natsugoeshoji clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc